RxDoctor Payments DataLook up a doctor →

Howard Ilivicky, MD

Psychiatry · Saint Charles, MONPI 1093711152

Payments from drug & device makers

$2,106,756in general payments, 2019–2025

Across 1,278 payments — averaging $1648.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$799K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$531K
  • Boehringer Ingelheim$352K
  • Sage Therapeutics, LLC$177K
  • Alkermes, Inc.$121K
  • Purdue Pharma L.p.$37K
  • plus $89K from 37 others
$1,500in research payments, 2019–2025

Across 8 payments — averaging $187.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC81$799,137
Otsuka Pharmaceutical Development & Commercialization, Inc.18$531,205
Boehringer Ingelheim27$352,007
Sage Therapeutics, LLC29$177,182
Alkermes, Inc.119$121,219
Purdue Pharma L.p.12$36,808
Adlon Therapeutics L.p.6$22,773
Boehringer Ingelheim Pharma GmbH & Co.kg30$17,569
Avanir Pharmaceuticals, Inc.12$12,384
Biohaven Pharmaceutical Holding Company Ltd.3$11,005
Boehringer Ingelheim International GmbH39$6,144
Biohaven Pharmaceuticals, Inc.2$2,668
Supernus Pharmaceuticals, Inc.45$2,158
Sunovion Pharmaceuticals Inc.82$1,412
AbbVie(2 entities)96$1,409
Otsuka America Pharmaceutical, Inc.88$1,339
Neurocrine Biosciences, Inc.63$1,169
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)63$1,031
Jazz Pharmaceuticals Inc.5$880
Teva Pharmaceuticals USA, Inc.54$871
Vanda Pharmaceuticals Inc.49$864
Takeda Pharmaceuticals U.S.A., Inc.59$808
Lundbeck LLC35$621
Johnson & Johnson31$553
Axsome Therapeutics, Inc.31$524
Neos Therapeutics, LP24$381
Bausch Health US, LLC23$368
Ironshore Pharmaceuticals Inc.21$349
Tris Pharma Inc23$330
Corium, LLC26$270
Merck18$262
Noven Therapeutics, LLC15$219
Acadia Pharmaceuticals Inc10$184
Idorsia Pharmaceuticals US Inc11$158
E.r. Squibb & Sons, L.L.C.5$97
Collegium Pharmaceutical, Inc.5$90
Almatica Pharma LLC4$89
Eisai Inc.5$79
Shire North American Group Inc4$66
Livanova USA, Inc.2$28
Biogen1$19
Currax Pharmaceuticals LLC1$13
Vertical Pharmaceuticals, LLC1$12

How this compares

$2,106,756 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri →

Medicare billing

Part B allowed, 2024
$92,061
Medicare patients
153
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Saint Charles

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →